Current guidelines recommend screening for liver cancer in high-risk groups for early and systematic treatment of liver cancer. However, the effectiveness of liver cancer screening in reducing liver cancer mortality has recently been challenged by the fact that most liver cancer patients are diagnosed at an advanced stage of the disease and have a low overall survival rate, and by the fact that it is not clear what subtypes of liver cancer are most effectively screened for. A study conducted by Professor Wu, Gastroenterology, Taichung Veterans General Hospital, Taiwan, China, suggests that shortening the ultrasound screening interval may reduce mortality from liver cancer and was recently published in Gut. The cohort study collected 52,823 patients with primary diagnosis of hepatocellular liver cancer from January 1, 2002 to December 31, 2007 across Taiwan, and was divided into 0-6 month group, 7-12 month group, 13-24 month group, 25-36 month group and never screened group (no liver cancer screening within 3 years) according to the time interval between their ultrasound screening. All patients were followed up from diagnosis of liver cancer until death or until the end of 2012. Cox proportional risk models were used to calculate the relative risk of each risk factor for mortality, and patients were adjusted for lead-effects bias to calculate treatment uptake rates and 5-year cumulative mortality. The study results showed treatment uptake rates of 24.3%, 26.9%, 22.9%, 21.3%, and 18.3% in the June, December, 24-month, 36-month, and never screened groups, respectively. The adjusted relative risk of mortality was 1.11, 1.23, 1.31, and 1.41 for the December, 24-month, 36-month, and never-screened groups, respectively, compared with the 6-month group. Multivariate subgroup analyses found that shorter intervals between screenings were associated with better clinical prognosis in almost all subgroups, particularly in younger patients and in those without diabetes and hepatitis B. Shorter screening intervals reduced overall mortality in patients with hepatocellular carcinoma, with shorter screening intervals associated with lower mortality. However, there was no linear relationship between the ultrasound screening interval and the rate of patients receiving treatment. there was no statistically significant difference between the 6-month group and the 12-month group in the rate of treatment received. Although the study was limited to ultrasound screening of high-risk patients and did not conduct a large-sample, multicenter, controlled study, it still provides a reference for the cost-effectiveness of regular liver cancer screening and the development of health policy.